Managing Heart Failure in Pregnancy or Post Partum

Karen Sliwa
The Hatter Institute for Cardiovascular Research in Africa (HICRA)
University of Cape Town
UCT Private Academic Hospital
www.hatter.uct.ac.za
Case 2

- 25 year old women
- Sudden onset of shortness of breath 4 weeks prepartum
- Medical Hx: Nil (no HT, no FHx, not smoking)
- Examination:
  - Obese (104 kg)
  - HR 120 bpm
  - BP 180/110
  - JVP raised
  - Lungs: pulmonary oedema
Case 2

- Differential diagnosis
  1. Pulmonary Embolus
  2. Pre-existing Hypertension
Case 2

CXR and ECG:
Case 2

- **echocardiography:**

11.20.24 hrs _[0007230].mp4
Case 2

Blood tests: HIV negative, D-dimers negative, normal Thyroid function test

**Diagnosis:** Hypertensive Heart Failure
Management of patient according to time of presentation

According to standard heart failure guidelines

- Not pregnant
- Early pregnancy: Diuretics, Hydralazine, Beta blocker
- Late pregnancy: Diuretics, Hydralazine, Beta blocker
- Post partum: Diuretics, Ace-inhibitor, Beta blocker

Effect on fetus
Managing acute heart failure due to PPCM/HT in pregnancy is no different than that applied to acute HF arising from any other cause.

Oxygen - in order to achieve an arterial oxygen saturation of ≥95 %, using, where necessary, non-invasive ventilation with a positive end-expiratory pressure (PEEP) of 5-7.5 cm H₂O.

Intravenous diuretics, when there is congestion and volume overload with an initial bolus of furosemide 20-40 mg i.v., is recommended.

Intravenous nitrate is recommended (e.g. nitroglycerine starting at 10-20 µg/min up to 200 µg/min) in patients with a systolic blood pressure > 110 mmHg and may be used with caution in patients with SBP between 90-110 mmHg.

Inotropic agents should be considered in patients with a low output state, indicated by signs of hypoperfusion.
**PPCM-management of chronic heart failure**

After delivery PPCM/HT heart failure should be treated in accordance with the current guidelines During pregnancy the following restrictions to these guidelines apply:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE-inhibitors and Angiotensin-II receptor blocker (ARBs)</strong></td>
<td>Contraindicated because of serious renal and other foetal toxicity (I-C). AT1-receptor blockers probably cause similar toxicity.</td>
</tr>
<tr>
<td><strong>Hydralazine and long acting nitrates</strong></td>
<td>It is believed that this combination can be used safely, instead of ACE-inhibitors/ARBs, in patients with PPCM.</td>
</tr>
<tr>
<td><strong>Beta-blockers</strong></td>
<td>Not shown to have teratogenic effects.</td>
</tr>
<tr>
<td></td>
<td>Beta-1 selective drugs preferred because beta-2 receptor blockade can have an anti-tocolytic action.</td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td>Should be used sparingly as can cause decreased placental blood flow</td>
</tr>
<tr>
<td><strong>Furosemide and hydrochlorothiazide</strong></td>
<td>Most frequently used</td>
</tr>
<tr>
<td><strong>Aldosterone antagonists</strong></td>
<td>Spironolactone thought to have antiandrogenic effects in first trimester. Eplerenone - effects on the human foetus uncertain, avoid during pregnancy.</td>
</tr>
</tbody>
</table>
Breast feeding

Based on the postulated negative effects of prolactin subfragments (*Hilfiker-Kleiner Cell 2007*), breastfeeding is not advised in patients with suspected PPCM, even if this practice is not fully evidence-based.

Several ACE-inhibitors (captopril, enalapril and quinapril) have been adequately tested in breastfeeding women.
Timing and mode of delivery

A team comprising a cardiologist, obstetrician, anaesthesiologist, neonatologist and intensive care physician) should discuss the planned mode and conduct of delivery in each case.

The primary consideration should be maternal cardiovascular benefit.

In general, spontaneous vaginal birth is preferable in women whose cardiac condition is well controlled, with an apparently healthy foetus.

Planned Caesarean section is preferred for women who are critically ill and in need of inotropic therapy or mechanical support.
Questions?